Patients who develop AF while being treated with BRAF inhibitor/MEK inhibitor should be managed in accordance with standard cardiology guidelines, although caution is required when considering anticoagulation, as concurrent treatment with MEK inhibitors66, 67, 68 and certain BRAF inhibitors64 may be associated with an increased risk of bleeding. Here, BRAF is linked to atrial fibrillation.